Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2025, and recent corporate updates.

Q3 2025 Earnings Call Transcript November 4, 2025 Exagen Inc. misses on earnings expectations. Reported EPS is $-0.19 EPS, ...

CARLSBAD, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, ...

Grew AVISE CTD test volume 16% compared to the third quarter of 2024. Expanded AVISE CTD trailing twelve-month ASP to $441 per test, an increase of $37 per test over the third quarter of 2024. Ended ...

Management maintained its revenue guidance, stating, "We remain on track to deliver $65 million to $70 million in revenue with the ability to be cash flow positive at the high end of our range, though ...

Revenue: $17.2 million in Q3, highest quarter in history, nearly 40% increase over Q3 2024. Year-to-Date Revenue: Approximately $50 million, 19% growth through Q3. Gross Margin: Just over 58% in Q3, ...

CARLSBAD, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following upcoming ...